Neoangiogenesis and relationship to nuclear p53 accumulation and vascular endothelial growth factor expression in advanced gastric carcinoma

Oncology

Volumn 57, Issue 2, 1999, Pages 164-172

  Saito, Hiroaki ^a   Tujitani, Shunichi ^a   Ikeguchi, Masahide ^a   Maeta, Michio ^a   Kaibara, Nobuaki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Gastric carcinoma; Microvessel; p53; Vascular endothelial growth factor

Indexed keywords

PROTEIN P53; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PRIORITY JOURNAL; STOMACH CARCINOMA; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL NUCLEUS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOKINES; MALE; MICROCIRCULATION; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032818878     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012025     Document Type: Article

References (42)

1. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
2. Bicknell R, Harris AL: Novel growth regulatory factors and tumor angiogenesis. Eur J Cancer 1991;27:781-784.
3. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
4. Gasparini G, Toi M, Verderio P, Ranieri G, Dante S, Bonoldi E, Boracchi P, Fanelli M, Tominaga T: Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: Subanalysis in node-positive and node-negative patients. Int J Oncol 1998;12:1117-1125.
5. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA: Relation of neovascularization to metastasis of non-small-cell lung cancer. Lancet 1992;340:145-146.
6. Giatromanolaki A, Koukourakis MI, Theodossiou D, Barbatis K, O'Byrne K, Harris AL, Gatter KC: Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. Clin Cancer Res 1997;3:2485-2492.
7. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T, Horiuchi T, Muraoka R, Iki M: Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. Cancer Res 1996;56:2671-2676.
8. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T: Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patients outcome in human gastric carcinoma. J Clin Oncol 1997;15:826-832.
9. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T: Association of tumour vasculature with tumour progression and overall survival of patients with non-early gastric carcinomas. Br J Cancer 1997;75:566-571.
10. Tanigawa N, Matsumura M, Amaya H, Kitaoka A, Shimomatsuya T, Lu C, Muraoka R, Tanaka T: Tumor vascularity correlates with the prognosis of patients with esophageal squamous cell carcinoma. Cancer 1997;79:220-225.
11. Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR, Ellis LM: Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997;132:541-546.
12. Obermair A, Wanner C, Bilgi S, Speiser P, Kaider A, Reinthaller A, Leodolter S, Gitsch G: Tumor angiogenesis in stage IB cervical cancer: Correlation of microvessel density with survival. Am J Obstet Gynecol 1998;178:314-319.
13. Rastinejad F, Polverini PJ, Bouck NP: Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989; 56:345-355.
14. Dameron KM, Volpert OV, Tainsky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-1584.
15. Kieser A, Weich HA, Brandner G, Marme D, Kolch W: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994;9: 964-969.
16. Fontanini G, Vignati S, Lucchi M, Calcinai A, Boldrini L, Chine S, Silvestri V, Angeletti CA, Basolo F, Bevilacqua G: Neoangiogenesis and p53 protein in lung cancer: Their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br J Cancer 1997;75:1295-1301.
17. Kang SM, Maeda K, Onoda N, Chung YS, Nakata B, Nishiguchi Y, Sowa M: Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer 1997;74:502-507.
18. Japanese Research Society for Gastric Cancer: Japanese Classification of Gastric Carcinoma. Tokyo, Kanehara, 1995.
19. Hamazoe R, Maeta M, Kaibara N: Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Cancer 1994;73:2048-2052.
20. Saito H, Tsujitani S, Ikeguchi M, Maeta M, Kaibara N: Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br J Cancer 1998;78:1573-1577.
21. Gomyo Y, Ikeda M, Osaki M, Tatebe S, Tsujitani S, Ikeguchi M, Kaibara N, Ito H: Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in survival of patients with advanced gastric carcinoma. Cancer 1997;79: 2067-2072.
22. Craft PS, Harris AL: Clinical prognostic significance of tumor angiogenesis. Ann Oncol 1994; 5:305-311.
23. Ellis LM, Takahashi Y, Fenoglio CJ, Cleary KR, Bucana CD, Evans DB: Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer 1998;34:337-340.
24. Klagsbrun M: Angiogenesis; in Sporn MB, Roberts AB (eds): Handbook of Experimental Pharmacology. Berlin, Springer, 1990, pp. 549-586.
25. Blood CH, Zetter BR: Tumor interactions with the vasculature: Angiogenesis and tumor metastasis. Biochim Biophys Acta 1990;1032:89-118.
26. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. Cancer Res 1986;46:467-473.
27. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858-863.
28. Toi M, Hoshina S, Takayanagi T, Tominaga T: Association of vascular endothelial growth factor expression with tumor angiogenesis and early response in primary breast cancer. Jpn J Cancer Res 1994;85:1045-1049.
29. Fontanini G, Vignati S, Boldrini L, Chine S, Silverstri V, Lucchi M, Mussi A, Angeletti CA, Bevilacqua G: Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell carcinoma. Clin Cancer Res 1997;3:861-865.
30. Finlay CA, Hinds PW, Levine AJ: The p53 protooncogene can act as a suppressor of transformation. Cell 1989;57:1083-1093.
31. Joypaul BV, Hopwood D, Newman EL, Qureshi S, Grant A, Ogston SA, Lane DP, Cuschieri A: The prognostic significance of the accumulation of p53 tumor-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 1994;69: 943-946.
32. Zeng ZS, Sarkis AS, Zhang ZF, Klimstra DS, Charytonowitz E, Guillem JG, Cordon-Cardo C, Cohen AM: p53 nuclear overexpression: An independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 1994;12:2043-2050.
33. Ebina M, Steinberg SM, Mulshine JL, Linnolia I: Relationship of p53 overexpression and upregulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 1994;54:2496-2503.
34. Volpert OV, Dameron KM, Bouch N: Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogen 1997;14:1495-1502.
35. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AL: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-538.
36. Lane D, Benchimol S: p53: Oncogene or anti-oncogene. Genes Dev 1990;4:1-8.
37. Bartek J, Iggo R, Gannon J, Lane DP: Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990;5:893-899.
38. Iggo R, Gatter K, Bartek J, Lane D, Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335:675-679.
39. Rodrigues NR, Rowan A, Smith MEF, Kerr IB, Bodmer WF, Gannon JV, Lane DP: p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990;87:7555-7559.
40. Tamura G, Kihana T, Nomura K, Terada M, Sugimura T, Hirohashi S: Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis. Cancer Res 1991;51:3056-3058.
41. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KMW, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996;2:985-991.
42. Mukhopadhyay D, Tsiokas L, Sukhatme VP: Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995;55: 6161-6165.